Description

• Potent and selective Foxo1 inhibitor (IC50 values are 33 nM at Foxo1 and >1 μM at Foxo3a and Foxo4); decreases Foxo-mediated promoter activity by 70%, 20% and 3% at Foxo1, Foxo4 and Foxo3, respectively
• Regulates gluconeogenesis both in vitro and in vivo
• Attenuates fasting plasma glucose level in diabetic db/db mice
• Also suppresses autophagy, adipocyte differentiation and soluble guanylyl cyclase expression
• Also inhibits STAT3 signaling in NSCLC
• Orally bioavailable.